Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGFR | P43088 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24676582 | 0.92 | PTGER4 (0.43) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL196388 | 0.90 | PTGER4 (0.55) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL29260289 | 0.89 | PTGER4 (0.43) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL196448 | 0.89 | PTGER4 (0.67) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Tromethamine SCHEMBL22633156 | 0.85 | PTGER4 (0.62) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Diethanolamine SCHEMBL28521337 | 0.84 | PTGER4 (0.60) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL26951178 | 0.83 | PTGER4 (0.55) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL24676880 | 0.81 | PTGER4 (0.51) | PTGER4PTGER2PTGDR | |
| SCHEMBL24676590 | 0.80 | NOTUM (0.36) | PTGER4PTGDR | |
| SCHEMBL32684932 | 0.79 | PTGER4 (0.67) | PTGER4PTGER2PTGDRTBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399339-A1 | HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399339-A1 | HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| CN-116783201-A | Heterocyclic amide derivative, preparation method and application thereof | 深圳众格生物科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022161422-A1 | HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳晶泰科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399339-A1 | HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 11/4885PTGDR 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.